Proinflammatory and vasoactive effects of Aβ in the cerebrovasculature

Annals of the New York Academy of Sciences

Volumn 977, Issue , 2002, Pages 65-76

  Townsend, K P ^a   Obregon, D ^a   Quadros, A ^a   Patel, N ^a   Volmar, Ch ^a   Paris, D ^a   Mullan, M ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Alzheimer's disease; Cerebrovasculature; COX 2 inhibitor; Mutant APP; Proinflammatory; Vasoactivity; amyloid peptide (A )

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; AMYLOID BETA PROTEIN; ENDOTHELIN 1; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA;

AGING; ALZHEIMER DISEASE; ANIMAL MODEL; AUTOPSY; BRAIN ARTERY; BRAIN ATHEROSCLEROSIS; BRAIN CIRCULATION; BRAIN PERFUSION; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CLINICAL FEATURE; CONFERENCE PAPER; CONTROLLED STUDY; DIABETES MELLITUS; HUMAN; HUMAN TISSUE; HYPERTENSION; MOUSE; NONHUMAN; RISK FACTOR; SENILE PLAQUE; SIGNAL TRANSDUCTION; STROKE; VASCULAR AMYLOIDOSIS; VASOCONSTRICTION;

ANIMALIA;

EID: 0036447712     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2002.tb04799.x     Document Type: Conference Paper

References (66)

1. Kalaria, R.N., M. Harshbarger-Kelly, D.L. Cohen & D.R.D. Premkumar. 1996. Neurobiology of aging; molecular aspects of inflammatory and immune responses in Alzheimer's disease. Neurobiol. Aging 17(5): 687-693.
2. Rogers, J., S. Webster, L.F. Lue et al. 1996. Inflammation and Alzheimer's disease pathogenesis. Neurobiol. Aging 17(5): 681-686.
3. McGeer, P.L. & E.G. McGeer. 1999. Inflammation of the brain in Alzheimer's disease: Implications for therapy. J. Leukocyte Biol. 65: 409-415.
4. Itagaki, S., P.L. McGeer, H. Akiyama et al. 1989. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J. Neuroimmunol. 24: 173-182.
5. Griffin, W.S., J.G. Sheng, G.W. Roberts & R.E. Mrak. 1995. Interleukin-1 expression in different plaque types in Alzheimer's disease: Significance in plaque evolution. J. Neuropathol. Exp. Neurol. 54(2): 276-281.
6. Lue, L.F., L. Brachova, W.H. Civin & J.J. Rogers. 1996. Inflammation, A-beta deposition, and neurofibrillary tangle formation as correlates of Alzheimer's disease neurodegeneration. Neuropathol. Exp. Neurol. 55(10): 1083-1088.
7. Ellis, R.J. et al. 1996. Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: The CERAD experience (part 15). Neurology 46: 1592-1596.
8. Hashimura, T., T. Kimura & T. Miyakawa. 1991. Morphological changes of blood vessels in the brain with Alzheimer's disease. Jpn. J. Psychiatry Neurol. 45: 661-665.
9. Kimura, T., T. Hashimura & T. Miyakawa. 1991. Observations of microvessels in the brain with Alzheimer's disease by scanning electron microscopy. Jpn. J. Psychiatry Neurol. 45: 671-676.
10. Buee, L., P.R. Hof & A. Delacourte. 1997. Brain microvascular changes in Alzheimer's disease and other dementias. Ann. N.Y. Acad. Sci. 826: 7-24.
11. Buee, L., P.R. Hof, C. Bouras et al. 1994. Pathological alterations of the cerebral microvasculature in Alzheimer's disease and related dementing disorders. Acta Neuropathol. 87: 469-480.
12. Fischer, V.W., A. Siddiqi & Y. Yusufaly. 1990. Altered angioarchitecture in selected areas of brains with Alzheimer's disease. Acta Neuropathol. 79: 672-679.
13. Mancardi, G.L., F. Perdelli, C. Rivano et al. 1980. Thickening of the basement membrane of cortical capillaries in Alzheimer's disease. Acta Neuropathol. 49: 79-83.
14. Kalaria, R.N. & P. Hedera. 1995. Differential degeneration of the cerebral microvasculature in Alzheimer's disease. NeuroReport 6: 477-480.
15. Kalaria, R.N. & A.B. Pax. 1995. Increased collagen content of cerebral microvessels in Alzheimer's disease. Brain Res. 705: 349-352.
16. Claudio, L. 1996. Ultrastructural features of the blood-brain barrier in biopsy tissue from Alzheimer's disease patients. Acta Neuropathol. 91: 6-14.
17. Kalaria, R.N. 2000. The role of cerebral ischemia in Alzheimer's disease. Neurobiol. Aging 21: 321-330.
18. Perry, G., M.A. Smith, C.E. McCann et al. 1998. Cerebrovascular muscle atrophy is a feature of Alzheimer's disease. Brain Res. 791: 63-66.
19. Martinez-Hernandez, A. & P.S. Amenta. 1983. The basement membrane in pathology. Lab. Invest. 48: 656-677.
20. Grammas, P. & R. Ovase. 2001. Inflammatory factors are elevated in brain microvessels in Alzheimer's disease. Neurobiol. Aging 22(6): 837-842.
21. Grammas, P. 2000. A damaged microcirculation contributes to neuronal cell death in Alzheimer's disease. Neurobiol. Aging 21(2): 199-205.
22. Grammas, P., U. Reimann-Philipp & P.H. Weigel. 2000. Cerebrovasculature-mediated neuronal cell death. Ann. N.Y. Acad. Sci. 903: 55-60.
23. Grammas, P., P. Moore & P.H. Weigel. 1999. Microvessels from Alzheimer's disease brains kill neurons in vitro. Am. J. Pathol. 154(2): 337-342.
24. de la Torre, J.C. 2002. Alzheimer disease as a vascular disorder: Nosological evidence. Stroke 33(4): 1152-1162.
25. de la Torre, J.C. 2000. Impaired cerebromicrovascular perfusion: Summary of evidence in support of its causality in Alzheimer's disease. Ann. N.Y. Acad. Sci. 924: 136-152.
26. Wisniewski, H.M. & J. Wegiel. 1993. Migration of perivascular cells into the neuropil and their involvement in beta-amyloid plaque formation. Acta Neuropathol. 85: 586-595.
27. Wisniewski, H.M., J. Wegiel, K.C. Wang & B. Lach. 1992. Ultrastructural studies of the cells forming amyloid in the cortical vessel wall in Alzheimer's disease. Acta Neuropathol. 84: 117-127.
28. Selkoe, D.J. 1996. Amyloid beta-protein and the genetics of Alzheimer's disease. J. Biol. Chem. 271: 8295-8298.
29. Lue, L.F., Y.M. Kuo, A.E. Roher et al. 1999. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol. 155: 853-862.
30. McLean, C.A, R.A. Cherny, F.W. Fraser et al. 1999. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 46: 860-866.
31. Natte, R. et al. 2001. Dementia in hereditary cerebral hemorrhage with amyloidosis-Dutch type is associated with cerebral amyloid angiopathy, but is independent of plaques and neurofibrillary tangles. Ann. Neurol. 50(6): 765-772.
32. Thomas, T., G. Thomas, C. McLendon et al. 1996. Beta-amyloid-mediated vasoactivity and vascular endothelial damage. Nature 380(6570): 168-171.
33. Crawford, F., C. Soto, Z. Suo et al. 1998. Alzheimer's beta-amyloid vasoactivity: Identification of a novel beta-amyloid conformational intermediate. FEBS Lett. 436(3): 445-448.
34. Crawford, F., Z. Suo, C. Fang & M. Mullan. 1998. Characteristics of the in vitro vasoactivity of beta-amyloid peptides. Exp. Neurol. 150(1): 159-168.
35. Niwa, K., V.A. Porter, K. Kazama et al. 2001. Beta-peptides enhance vasoconstriction in cerebral circulation. Am. J. Physiol. Heart Circ. Physiol. 281(6): H2417-H2424.
36. Price, J.M, X. Chi, G. Hellermann & E.T. Sutton. 2001. Physiological levels of beta-amyloid induce cerebral vessel dysfunction and reduce endothelial nitric oxide production. Neurol. Res. 23(5): 506-512.
37. Paris, D., T. Town, T. Mori et al. 2000. Soluble beta-amyloid peptides mediate vasoactivity via activation of a pro-inflammatory pathway. Neurobiol. Aging 21(2): 183-197.
38. Paris, D., T. Town, T. Parker et al. 2000. Aβ vasoactivity: An inflammatory reaction. Ann. N.Y. Acad. Sci. 903: 97-109.
39. Hoozemans, J.J., A.J. Rozemuller, I. Janssen et al. 2001. Cyclooxygenase expression in microglia and neurons in Alzheimer's disease and control brain. Acta Neuropathol. 101(1): 2-8.
40. Montine, T.J., K.E. Sidell, B.C. Crews et al. 1999. Elevated CSF prostaglandin E2 levels in patients with probable AD. Neurology 53(7): 1495-1498.
41. Paris, D., K.P. Townsend, D.F. Obregon et al. 2002. Pro-inflammatory effect of freshly solubilized β-amyloid peptides in the brain. J. Prostaglandins Other Lipid Mediators. In press.
42. Li, D.Y., P. Hardy, D. Abran et al. 1997. Key role for cyclooxygenase-2 in PGE2 and PGF2alpha receptor regulation and cerebral blood flow of the newborn. Am. J. Physiol. 273: R1283-R1290.
43. Hoffman, S.W., S. Moore & E.F. Ellis. 1997. Isoprostanes: Free radical-generated prostaglandins with constrictor effects on cerebral arterioles. Stroke 28: 844-849.
44. I-40 peptide. Exp. Neurol. 152(1): 116-122.
45. Pasinetti, G.M. & P.S. Aisen. 1998. Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain. Neuroscience 87(2): 319-324.
46. Ho, L., C. Pieroni, D. Winger et al. 1999. Regional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer's disease. J. Neurosci. Res. 57(3): 295-303.
47. van Ryn, J. & M. Pairet. 1999. Clinical experience with cyclooxygenase-2 inhibitors (review). Inflamm. Res. 48(5): 247-254.
48. Lim, G.P., F. Yang, T. Chu et al. 2001. Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol. Aging 22(6): 983-991.
49. Lim, G.P., F. Yang, T. Chu et al. 2000. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J. Neurosci. 20(15): 5709-5714.
50. Stewart, W.F., C. Kawas, M.C. Corrada & E.J. Metter. 1997. Risk of Alzheimer's disease and duration of NSAID use. Neurology 48(3): 626-632.
51. McGeer, P.L., M. Schulzer & E.G. McGeer. 1996. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies. Neurology 47(2): 425-432.
52. Fendrick, A.M. 2002. Developing an economic rationale for the use of selective COX-2 inhibitors for patients at risk for NSAID gastropathy. Clevel. Clin. J. Med. 69(suppl. 1): SI59-SI64.
53. Matsuoka, Y., M. Picciano, B. Malester et al. 2001. Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease. Am. J. Pathol. 158(4): 1345-1354.
54. Xiang, Z., L. Ho, J. Valdellon et al. 2002. Cyclooxygenase (COX)-2 and cell cycle activity in a transgenic mouse model of Alzheimer's disease neuropathology. Neurobiol. Aging 23(3): 327-334.
55. Suo, Z., J. Humphrey, A. Kundtz et al. 1998. Soluble Alzheimer's beta-amyloid constricts the cerebral vasculature in vivo. Neurosci. Lett. 257(2): 77-80.
56. Suo, Z., G. Su, A. Placzek et al. 2000. Aβ vasoactivity in vivo. Ann. N.Y. Acad. Sci. 903: 156-163.
57. Iadecola, C., F. Zhang, K. Niwa et al. 1999. SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein. Nat. Neurosci. 2(2): 157-161.
58. Thomas, T., E.T. Sutton, A. Hellermann & J.M. Price. 1997. Beta-amyloid-induced coronary artery vasoactivity and endothelial damage. J. Cardiovasc. Pharmacol. 30(4): 517-522.
59. 1-40 reproduces cerebrovascular alterations resulting from amyloid precursor protein overexpression in mice. Cereb. Blood Flow Metab. 20(12): 1659-1668.
60. Niwa, K., K. Kazama, S.G. Younkin et al. 2002. Alterations in cerebral blood flow and glucose utilization in mice overexpressing the amyloid precursor protein. Neurobiol. Dis. 9(1): 61-68.
61. 1-40-related reduction in functional hyperemia in mouse neocortex during somatosensory activation. Proc. Natl. Acad. Sci. U.S.A. 97(17): 9735-9740.
62. Wahlund, L.O., H. Basun, O. Almkvist et al. 1999. A follow-up study of the family with the Swedish APP 670/671 Alzheimer's disease mutation. Dement. Geriatr. Cogn. Disord. 10(6): 526-533.
63. Paris, D., K. Townsend, D.F. Obregon et al. 2002. Inhibition of angiogenesis by the Alzheimer's Aβ peptides. Nat. Med. Submitted.
64. Wendling, W.W. & C. Harakal. 1991. Effects of prostaglandin F2α and thromboxane A2 analogue on bovine cerebral arterial tone and calcium fluxes. Stroke 22(1): 66-72.
65. Niwa, K., K. Kazama, L. Younkin et al. 2002. Cerebrovascular autoregulation is profoundly impaired in mice overexpressing amyloid precursor protein. Am. J. Physiol. Heart Circ. Physiol. 283(1): H315-H323.
66. Zhang, F., C. Eckman, S. Younkin et al. 1997. Increased susceptibility to ischemic brain damage in transgenic mice overexpressing the amyloid precursor protein. J. Neurosci. 17(20): 7655-7661.